JP2021535175A5 - - Google Patents

Info

Publication number
JP2021535175A5
JP2021535175A5 JP2021512244A JP2021512244A JP2021535175A5 JP 2021535175 A5 JP2021535175 A5 JP 2021535175A5 JP 2021512244 A JP2021512244 A JP 2021512244A JP 2021512244 A JP2021512244 A JP 2021512244A JP 2021535175 A5 JP2021535175 A5 JP 2021535175A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
liver disease
fatty liver
Prior art date
Application number
JP2021512244A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020006631A5 (https=
JP2021535175A (ja
JP7399949B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/050915 external-priority patent/WO2020006631A1/en
Publication of JP2021535175A publication Critical patent/JP2021535175A/ja
Publication of JP2021535175A5 publication Critical patent/JP2021535175A5/ja
Publication of JPWO2020006631A5 publication Critical patent/JPWO2020006631A5/ja
Application granted granted Critical
Publication of JP7399949B2 publication Critical patent/JP7399949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021512244A 2018-07-06 2019-07-03 非アルコール性脂肪性肝炎治療のための組成物及び方法 Active JP7399949B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694848P 2018-07-06 2018-07-06
US62/694,848 2018-07-06
US201962809351P 2019-02-22 2019-02-22
US62/809,351 2019-02-22
PCT/CA2019/050915 WO2020006631A1 (en) 2018-07-06 2019-07-03 Compositions and methods for treating non-alcoholic steatohepatitis

Publications (4)

Publication Number Publication Date
JP2021535175A JP2021535175A (ja) 2021-12-16
JP2021535175A5 true JP2021535175A5 (https=) 2022-07-12
JPWO2020006631A5 JPWO2020006631A5 (https=) 2022-07-12
JP7399949B2 JP7399949B2 (ja) 2023-12-18

Family

ID=69060680

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512244A Active JP7399949B2 (ja) 2018-07-06 2019-07-03 非アルコール性脂肪性肝炎治療のための組成物及び方法

Country Status (6)

Country Link
US (1) US11744808B2 (https=)
EP (2) EP3817749A4 (https=)
JP (1) JP7399949B2 (https=)
CN (1) CN112654357B (https=)
CA (1) CA3105850A1 (https=)
WO (1) WO2020006631A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020191501A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bemithyl and derivatives for treating lung disease, fatty liver disease, and kidney disorders
WO2020191503A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
IT202100014177A1 (it) * 2021-05-31 2022-12-01 Sunnutrapharma S R L Utilizzo della istradefillina per ridurre la fibrosi d’organo
CN115778957B (zh) * 2022-11-04 2024-06-21 天津中医药大学 千金藤素及包含其的组合物用于预防或治疗酒精性肝病的应用
CN120346213B (zh) * 2025-05-13 2025-10-24 中国医科大学 CD39抑制剂或A2a受体抑制剂在制备治疗非酒精性脂肪肝炎产品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2175229C2 (ru) * 1999-12-22 2001-10-27 Научно-исследовательский институт фармакологии РАМН Анксиолитическое средство
JP3885135B2 (ja) * 2000-10-10 2007-02-21 幸彦 松田 C型又は非b非c型肝炎ウイルスによる肝機能異常の改善剤
RU2261709C2 (ru) * 2003-08-15 2005-10-10 Государственное учреждение Научно-исследовательский институт фармакологии Российской Академии медицинских наук Психостимулирующее средство
ATE494892T1 (de) * 2007-03-30 2011-01-15 Cardoz Ab Kombination zur verwendung bei der behandlung von entzündlichen erkrankungen
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
WO2012157290A1 (ja) * 2011-05-19 2012-11-22 富士化学工業株式会社 非アルコール性脂肪性肝炎の予防改善剤
WO2013125543A1 (ja) * 2012-02-20 2013-08-29 武田薬品工業株式会社 複素環化合物
RU2547141C1 (ru) * 2014-02-28 2015-04-10 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) Способ получения n-(4-бромфенил)-n-(2-адамантил)амина (бромантана)
WO2017100500A1 (en) * 2015-12-11 2017-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vesicle containing metallic nanoparticle and method for production thereof

Similar Documents

Publication Publication Date Title
JP2021535175A5 (https=)
JP2018507914A5 (https=)
WO2018234568A3 (en) HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
JP2021530746A5 (https=)
WO2018136264A9 (en) Pyridine compounds as allosteric shp2 inhibitors
JP2014094951A5 (https=)
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
JP2021529829A5 (https=)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
WO2015095354A3 (en) Compositions and methods for treating fatty tissue buildup
JP2015038135A5 (https=)
ES3061069T3 (en) Peptides for treatment and prevention of nonalcoholic fatty liver disease
JP2016511753A5 (https=)
WO2013183062A3 (en) Palatable formulations of ibuprofen
JP2021522247A5 (https=)
JP2017515854A5 (https=)
JP2016510326A5 (https=)
JP2024028337A5 (https=)
JP2015537009A5 (https=)
CN111868056A (zh) 1,2,4-噁二唑类化合物及其制备方法和医药用途
JP2015510916A5 (https=)
JP2021514365A5 (https=)
JP2009541409A5 (https=)